With future approvals of FABHALTA, the market size is expected to expand significantly in the coming years, driven by its potential to address unmet medical needs across multiple conditions like IgAN, PNH, and other complement-driven diseases. LAS VEGAS, April 29, 2025 /PRNewswire/ –…
